SOURCE: Tulip BioMed, Inc.

September 19, 2006 08:28 ET

Tulip BioMed to Demonstrate Disposable Liposuction Prototypes at ASPS Tradeshow

New Instruments Will Support Top Cosmetic Surgery Market With Safer Instrumentation

SAN DIEGO, CA -- (MARKET WIRE) -- September 19, 2006 -- Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it will exhibit prototypes of its new disposable cannulas for the liposuction market in booth 1352 at "Plastic Surgery 2006" in San Francisco from Oct 6-11. This tradeshow is the plastic surgery industry's largest annual conference, and is produced by the American Society of Plastic Surgeons (ASPS).

Liposuction is the number one cosmetic surgery procedure undertaken in the United States, with 455,489 liposuction procedures completed in 2005, according to statistics sourced by Tulip BioMed is introducing a series of five, versatile, disposable cannula models that will work with all standard aspiration machines as well as the syringe system method of liposuction.

In addition to the liposuction cannulas, Tulip BioMed will also be demonstrating its disposable harvester and injector cannulas for fat transfer and microsurgeries, which are already selling on the market. The liposuction instruments, like the others, use Tulip BioMed's patented SuperLuerLok and Syringe Hub adapter technologies, and are coated both inside and out with a hydrophilic coating that protects the surrounding tissue. Tulip BioMed expects to be shipping the liposuction instruments by year-end.

Darin Andersen, Tulip BioMed's president and COO, said, "The global market for body shaping devices continues to grow at a strong pace. We thought it important to introduce these new instruments at this conference to let the industry know that safer, better performing instruments for liposuction are soon to hit the market."

According to research firm Medical Insight Inc., in its "Global Body Shaping Market Analysis" report issued in March 2006, liposuction accounted for almost 69% of cosmetic procedure fees in 2005. Liposuction is a procedure that virtually guarantees removal of small fat deposits in a single procedure.

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: Products are available for sale at

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Beth Walsh
    Clearpoint Agency, Inc.
    Email Contact